Date: April 25, 2022 Rachel Breslau (RB): How did you get involved in health economics and outcomes research? James Chambers (JC): It’s a long stor...
Read moreA New Era for the CEA Registry Attend our webinar Wednesday, May 4, 2022 12:00 PM – 1:00 PM (Eastern Time) The CEA Registry is excited to an...
Read moreDate: March 10, 2022Rachel Breslau (RB): How did you get involved in health economics and outcomes research? Tara Lavelle (TL): I was looking for rese...
Read moreTara A. Lavelle, Xue Feng, Marlena Keisler, Joshua T. Cohen, Peter J. Neumann, Daryl Prichard, Brock E. Schroeder, Daria Salyakina, Paula S. Espinal, Samuel B. Weidner, Jill L. Maron, Cost-effectiveness of exome and genome sequencing for children with rare and undiagnosed conditions, Genetics in Medicine, 2022, , ISSN 1098-3600, https://doi.org/10.1016/j.gim.2022.03.005.
Meghan I. Podolsky, Isabel Present, Peter J. Neumann, David D. Kim, A Systematic Review of Economic Evaluations of COVID-19 Interventions: Considerations of Non-health Impacts and Distributional Issues, Value in Health, 2022, , ISSN 1098-3015, https://doi.org/10.1016/j.jval.2022.02.003.
Siyu Ma, Natalia Olchanski, Joshua T. Cohen, Daniel A. Ollendorf, Peter J. Neumann, David D. Kim, The Impact of Broader Value Elements on Cost-Effectiveness Analysis: Two Case Studies, Value in Health, 2022, , ISSN 1098-3015, https://doi.org/10.1016/j.jval.2022.01.025.
Neumann PJ, Garrison LP, Willke RJ. The History and Future of the “ISPOR Value Flower”: Addressing Limitations of Conventional Cost-Effectiveness Analysis. Value in Health. 2022 March 9. DOI:https://doi.org/10.1016/j.jval.2022.01.010
Margaretos NM, Bawa K, Engmann NJ, Chambers JD. Patients' access to rare neuromuscular disease therapies varies across US private insurers. Orphanet J Rare Dis. 2022 Feb 5;17(1):36. doi: 10.1186/s13023-022-02182-3.
The Certainty Of Uncertainty In Health Technology Assessment, Health Affairs Forefront, January 26, 2022. DOI: 10.1377/forefront.20220125.37540
Medicare’s Aducanumab Decision Highlights Needed Reforms To FDA And CMS Regulatory Pathways, Health Affairs Forefront, January 25, 2022. DOI: 10.1377/forefront.20220121.566837
Ma, S., Lavelle, T.A., Ollendorf, D.A. et al. Herd Immunity Effects in Cost-Effectiveness Analyses among Low- and Middle-Income Countries. Appl Health Econ Health Policy (2022). https://doi.org/10.1007/s40258-021-00711-y
Mulé C, Sliwinski, SK, Israel R, Lavelle TA, Developmental Behavioral Pediatrician Perspectives on Decision-Making in Early Treatment Planning for Children with Autism Spectrum Disorder, Journal of Developmental & Behavioral Pediatrics: October 12, 2021 - Volume - Issue - doi: 10.1097/DBP.0000000000001002
Chambers, J.D., Silver, M.C., Berklein, F.C. et al. Are Medical Devices Cost-Effective?. Appl Health Econ Health Policy (2021). https://doi.org/10.1007/s40258-021-00698-6
Hendrix N, Kim DD, Patel KS, Devine B. Differences in the Selection of Health State Utility Values by Sponsorship in Published Cost-Effectiveness Analyses. Med Decis Making. 2021 Apr;41(3):366-372. doi: 10.1177/0272989X20985821. Epub 2021 Jan 15. PMID: 33451278; PMCID: PMC7987800.
Chambers JD, Margaretos NM, Enright DE, Wang R, Ye X. Is an Orphan Drug's Cost-Effectiveness Associated with US Health Plan Coverage Restrictiveness? Pharmacoeconomics. 2021 Oct 26. doi: 10.1007/s40273-021-01096-5
Madison C. Silver, Peter J. Neumann, Siyu Ma, David D. Kim, Joshua T. Cohen, Mawuli Nyaku, Craig Roberts, Anushua Sinha, Daniel A. Ollendorf, Frequency and impact of the inclusion of broader measures of value in economic evaluations of vaccines, Vaccine, 2021,
Margaretos NM, Patel AM, Panzer AD, Lai RC, Whiteley J, Chambers JD. Variation in access to hemophilia A treatments in the United States. J Med Econ. 2021 Jan-Dec;24(1):1143-1148
Lin P, Neumann PJ. Valuing Alzheimer Disease Therapies—Considering Costs and Benefits Beyond the Patient. JAMA Netw Open. 2021;4(10):e2131913. doi:10.1001/jamanetworkopen.2021.31913
Our team of experienced, dedicated researchers is led by health economists Peter Neumann and Josh Cohen. Together we produce cutting-edge health care cost-effectiveness research.
Meet the CEVR TeamOur comprehensive databases provide the information individuals and organizations need to analyze the benefits, risks, and costs of strategies to improve health and health care.
The CEA Registry is a comprehensive database of 9,080 cost-utility analyses on a wide variety of diseases and treatments.
View RegistryThe GH CEA Registry is the first comprehensive database to compile articles utilizing the “cost-per-DALY averted” metric to measure the efficacy of health interventions.
View RegistryThe Specialty Drug Evidence and Coverage (SPEC) Database is a new data resource developed with the goal of providing an empirical basis to commercial payer specialty drug coverage.
View Database